COMPANY

Context Therapeutics

HQ: Philadelphia, PA source · contexttherapeutics.com ↗ · Mid-Atlantic

Keywords: antibody bispecific antibody oncology solid tumors cancer Colorectal Cancer Breast Cancer Triple Negative Breast Cancer Urothelial Cancer Platinum-resistant Ovarian Cancer Testicular Cancer Endometrial Cancer Mesothelin-Expressing Tumors Epithelial Ovarian Cancer Advanced Malignant Pleural Mesothelioma Advanced Malignant Peritoneal Mesothelioma Pancreatic Adenocarcinoma Advanced or Metastatic Lung Adenocarcinoma Metastatic Cholangiocarcinoma Advanced Cholangiocarcinoma Non-resectable Mesothelin-expressing Advanced Cancers Mesothelin-positive Advanced Malignant Solid Tumors castration resistant prostate cancer CT-202 CTIM-76 CT-95

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)1NIH grants

Timeline

2026-09 Trial start 1: A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers source ↗
May 18, 2026 Partnership Partnership / licensing: $4.5M (upfront, as published), announced May 18, 2026. Source: SEC filing. source ↗
Mar 31, 2025 Trial start Phase 1: CT-95 in Advanced Cancers Associated With Mesothelin Expression source ↗
Jul 10, 2024 Trial start 1: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors source ↗
2023-06 Trial start Phase 1/Phase 2: A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer source ↗
Dec 2, 2022 Trial start Phase 1/Phase 2: Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · CT-95 in Advanced Cancers Associated With Mesothelin Expression · NCT06756035
May 31, 2028 (ESTIMATED) · 1 · A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors · NCT06515613
2030-01 (ESTIMATED) · 1 · A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers · NCT07545122

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

May 18, 2026 Partnership / licensing: $4.5M (upfront, as published), announced May 18, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07545122	A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers	1	Recruiting	2026-09	2030-01 (estimated)
NCT06515613	A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors	1	Recruiting	Jul 10, 2024	May 31, 2028 (estimated)
NCT05618613	Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer	Phase 1/Phase 2	Terminated	Dec 2, 2022	Jun 23, 2023 (actual)
NCT06756035	CT-95 in Advanced Cancers Associated With Mesothelin Expression	Phase 1	Recruiting	Mar 31, 2025	2026-12 (estimated)
NCT06938711	A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer	Phase 1/Phase 2	Withdrawn	2023-06	2023-11 (estimated)

NIH awards 1

Annual award amounts. Total $225K.

Sep 14, 2016 NIH award 1R43CA206691-01A1 FY2016: $225,222 awarded for that fiscal year; activity R43 (SBIR); PI LEHR, MARTIN; recipient as written: CONTEXT THERAPEUTICS, LLC, PHILADELPHIA, PA. A Potent Small Molecule Sigma1 Modul source ↗